VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Gilead Sciences, Inc. $GILD

Key Points

• Virginia Retirement Systems ET Al acquired approximately 1.28 million shares of Gilead Sciences, valued at about $141.63 million, making it the firm's 11th largest position.
• Gilead Sciences reported $2.01 EPS for the last quarter, surpassing expectations, with $7.08 billion in revenue, showing a 1.4% increase year-over-year.
• The company recently announced a quarterly dividend of $0.79 per share, representing an annualized yield of 2.6% and indicating a strong commitment to shareholder returns.

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,277,495 shares of the biopharmaceutical company's stock, valued at approximately $141,636,000. Gilead Sciences makes up 1.0% of VIRGINIA RETIREMENT SYSTEMS ET Al's investment portfolio, making the stock its 11th biggest position. VIRGINIA RETIREMENT SYSTEMS ET Al owned about 0.10% of Gilead Sciences at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock worth $13,162,606,000 after acquiring an additional 1,942,433 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock worth $1,541,302,000 after purchasing an additional 1,520,809 shares during the period. Nuveen LLC bought a new position in Gilead Sciences during the 1st quarter valued at $620,415,000. Finally, Nordea Investment Management AB increased its position in shares of Gilead Sciences by 39.8% during the 2nd quarter. Nordea Investment Management AB now owns 3,956,933 shares of the biopharmaceutical company's stock valued at $436,648,000 after purchasing an additional 1,126,886 shares during the period. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

GILD stock opened at $122.81 on Friday. Gilead Sciences, Inc. has a one year low of $85.60 and a one year high of $124.11. The firm has a 50-day moving average of $115.22 and a two-hundred day moving average of $110.52. The firm has a market capitalization of $152.38 billion, a PE ratio of 24.46, a P/E/G ratio of 0.84 and a beta of 0.34. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the firm posted $2.01 earnings per share. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences's dividend payout ratio is presently 62.95%.

Analysts Set New Price Targets

GILD has been the subject of several research analyst reports. Royal Bank Of Canada upped their price objective on Gilead Sciences from $98.00 to $100.00 and gave the company a "sector perform" rating in a report on Wednesday, October 8th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Rothschild & Co Redburn raised their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research report on Friday, September 12th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Finally, Cantor Fitzgerald raised their target price on shares of Gilead Sciences from $129.00 to $135.00 and gave the stock an "overweight" rating in a report on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $119.17.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the transaction, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the transaction, the insider directly owned 110,193 shares in the company, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,500 shares of company stock valued at $8,281,540 over the last quarter. Company insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.